Press release
US & EU Melanoma Therapeutics Market (2033): Growth Drivers, Investment Opportunities
US & EU Melanoma Therapeutics Market Size 2025
US & EU Melanoma Therapeutics market reached US$ 3.89 billion in 2024 and is expected to reach US$ 8.99 billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033.
Download Free Sample PDF Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/us-and-eu-melanoma-therapeutics-market?kb
United States: Recent Developments in Melanoma Therapeutics
✅ Feb 2026: The FDA granted Orphan Drug Designation to IFx-2.0 from TuHURA Biosciences for treating stage IIB-IV cutaneous melanoma, based on Phase 1 safety and benefit data in anti-PD-1 refractory patients.
✅ Strategic priorities highlight ongoing Phase 3 clinical trials for KIMMTRAK (tebentafusp) in metastatic and cutaneous melanoma, with enrollment expected to complete in 1H 2026 and potential data later this year.
✅ Long-term Phase 1/2 results for IO Biotech's peptide vaccine IO102-IO103 in metastatic melanoma showed a median progression-free survival of 25.5 months, supporting a planned Phase 3 trial in first-line advanced melanoma.
✅ Scancell Ltd. progressed its DNA ImmunoBody® candidate iSCIB1+ for advanced melanoma, clearing an IND and positioning for Phase 3 study initiation in 2026 following good Phase 2 results.
✅ The melanoma clinical trial landscape continues to expand, with multiple programs (including targeted therapies and immunotherapies) advancing through Phase 1/2 and Phase 3 stages.
European Union: Recent Developments Impacting Melanoma
✅ Oct 2025: IDEAYA Biosciences presented positive Phase 2 data at ESMO 2025 for darovasertib in neoadjuvant treatment of primary uveal melanoma, with high tumor shrinkage and eye preservation rates; the drug has Breakthrough Therapy Designation in the US.
✅ Broader melanoma clinical activity in the EU includes international Phase I/II trials (e.g., advanced melanoma vaccine and TCR-T cell therapies), with readouts expected by the end of 2025 and beyond, reflecting a robust development ecosystem.
✅ European research forums and conferences continue to highlight melanoma immunomodulation and target biology, supporting future multi-modal therapeutic approaches.
Latest Mergers & Acquisitions (M&A)
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Day One finalized the buyout of Mersana, adding clinical-stage ADC Emi-Le to its oncology pipeline ($129M upfront; up to $285M with milestone-based CVRs)
Major Top Key Players: OMNSA
Growth Forecast Projection:
The US & EU Melanoma Therapeutics Market is anticipated to rise at a considerable rate during the forecast period, between 2026 and 2033. In 2025, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Key Developments:
✅ February 2026 - United States: Leading biopharmaceutical companies expanded indications for immune checkpoint inhibitors and combination immunotherapies to improve progression-free survival in advanced and metastatic melanoma patients.
✅ January 2026 - Europe: Regulatory authorities supported accelerated review pathways for next-generation targeted therapies and personalized melanoma treatments, strengthening innovation across the EU oncology landscape.
✅ December 2025 - United States: Clinical trials evaluating novel PD-1/PD-L1 inhibitors and adoptive T-cell therapies reported promising mid-stage results, boosting investment in advanced immuno-oncology pipelines.
✅ November 2025 - Europe: Oncology centers increased adoption of biomarker-driven treatment approaches, enabling more precise patient stratification and improved response rates in metastatic melanoma.
✅ October 2025 - United States: Strategic collaborations between biotech firms and research institutes accelerated development of combination regimens integrating immunotherapy with BRAF/MEK inhibitors.
✅ August 2025 - Europe: Healthcare systems expanded reimbursement coverage for innovative melanoma therapeutics, supporting broader patient access to high-cost biologics and targeted drugs.
✅ June 2025 - United States: Rising melanoma incidence rates and growing awareness campaigns encouraged early diagnosis initiatives, indirectly supporting demand for advanced therapeutic interventions.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=us-and-eu-melanoma-therapeutics-market?kb
Regional Analysis for Market:
⇥ United States: 58% - Dominates the market due to advanced immunotherapy adoption, strong clinical pipeline, and high healthcare expenditure.
⇥ European Union: 42% - Significant share driven by increasing melanoma incidence, expanding access to targeted therapies, and supportive regulatory frameworks.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/us-and-eu-melanoma-therapeutics-market?kb
Key Segmentations:
By Type
• Superficial Spreading Melanoma - Most common type, driving demand for early-stage treatments.
• Nodular Melanoma - Aggressive progression leads to increased adoption of advanced therapies.
• Lentigo Maligna & Acral Lentiginous Melanoma - Growing awareness and improved diagnostics support therapeutic uptake.
By Therapy
• Immunotherapy - Leading treatment option with strong clinical outcomes across advanced melanoma cases.
• Targeted Therapy - Precision oncology adoption drives treatment for mutation-specific patients.
• Surgery & Radiation Therapy - Standard care for early-stage melanoma, often used with adjuvant therapies.
Market Growth Drivers
✅ Rising Incidence Rates - Melanoma cases continue to surge due to excessive UV exposure (sunbathing, tanning beds) and climate factors; the US expects 105,000 new invasive cases in 2025, with similar upward trends in Europe driving urgent demand for treatments.
✅ Breakthroughs in Therapies - Immunotherapies like Keytruda (pembrolizumab) and Opdivo block cancer evasion, while targeted drugs and combos tackle resistance; personalized mRNA vaccines (e.g., Moderna's intismeran autogene + Keytruda) sustain 49% reduction in recurrence/death risk over 5 years.
✅ Regulatory and Policy Boosts - Fast-track approvals from FDA and EMA accelerate access, including AI-genomic tools in the US and expanded reimbursements in the EU, plus government campaigns and trial funding enhance availability.
✅ Awareness and Early Detection - Growing public education and screening catch melanoma earlier (highly treatable stage), supported by aging populations where risk increases with age, boosting overall market demand.
✅ Investment and Innovation - Billions from big pharma (Merck, Bristol-Myers Squibb, Novartis) fuel strong pipelines against resistance and rare subtypes; cross-border collaborations improve affordability and speed up effective new options.
Contact Us For Custom Research: https://www.datamintelligence.com/custom-research?kb
Empower your strategy with real-time competitor intelligence, forward-looking forecasts, and comprehensive global investment insights all in one place.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release US & EU Melanoma Therapeutics Market (2033): Growth Drivers, Investment Opportunities here
News-ID: 4399104 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Fucoidan Market expeted to reach US$ 202.6 million by 2030., United States Leads …
Market Size and Growth
Fucoidan Market reached US$ 90.5 million in 2022 and is expected to reach US$ 202.6 million by 2030, growing with a CAGR of 10.6% during the forecast period 2024-2031.
United States: Recent Industry Developments
✅ February 2026: Nutraceutical companies expanded fucoidan-based dietary supplements targeting immune health and anti-inflammatory benefits.
✅ January 2026: Clinical research initiatives progressed evaluating fucoidan's potential in oncology supportive care applications.
✅ December 2025: U.S. wellness brands introduced…
Ambulatory Blood Pressure Monitoring Devices Market Size to Reach US$ 3.42 Billi …
The Ambulatory Blood Pressure Monitoring Devices Market reached US$ 1.33 billion in 2024, up from US$ 1.21 billion in 2023, and is projected to grow significantly to US$ 3.42 billion by 2033, expanding at a CAGR of 11.2% during the forecast period 2025 to 2033. The market is witnessing strong momentum due to the rising global burden of hypertension, increasing awareness of cardiovascular risks, and the growing clinical preference for…
Closed System Transfer Devices Market Set for Explosive Growth to US$ 1968.26 Mi …
The Global Closed System Transfer Devices (CSTD) market reached US$ 718.29 million in 2024 and is expected to reach US$ 1968.26 million by 2033, growing at a CAGR of 11.7% during the forecast period 2025-2033.
Market expansion is propelled by rising technological advancements in CSTD design, such as intuitive locking mechanisms and improved compatibility with drug containers, enhancing user safety during hazardous drug handling. The increasing prevalence of cancer and widespread…
Bioliquid Heat and Power Generation Market Poised for Expansion to USD 3,878.7 T …
The global Bioliquid Heat and Power Generation Market size was estimated at USD 2,650.7 thousand in 2024 and is projected to reach USD 3,878.7 thousand by 2030, growing at a CAGR of 6.6% from 2025 to 2030. Rising demand for renewable energy, supportive government policies promoting bioenergy adoption, and increasing investments in sustainable power infrastructure are driving market growth. Additionally, growing focus on carbon emission reduction and efficient waste-to-energy utilization…
More Releases for Melanoma
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period?
The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment…
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market?
The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt…
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market?
The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in…
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Qiagen NV
• Sun Pharmaceutical Industries Ltd…
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
